Novavax To Report 2012 Fourth-Quarter And Year-End Financial Results On March 1, 2013

ROCKVILLE, Md., Feb. 22, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that it will report its 2012 fourth-quarter and year-end financial results on Friday, March 1, 2013, before the U.S. financial markets open. The announcement will be followed by a webcast and conference call hosted by Stanley C. Erck, President and Chief Executive Officer, and other members of senior management at 10:00 a.m. Eastern time. The webcast and conference call will be available at www.novavax.com under Investor Info/Events. The dial-in number for the conference call is 1 [phone] (U.S. or Canada) or 1 [phone] (International). Webcast and telephone replays of the conference call will be available shortly after the completion of the call. To access the replay by telephone, dial 1 [phone] (Domestic) or 1 [phone] (International) and use passcode 13572606.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company creating vaccines to address a broad range of infectious diseases worldwide. Using innovative recombinant protein nanoparticle vaccine technology, as well as new and efficient manufacturing approaches, the company produces vaccine candidates to combat diseases, with the goal of allowing countries to better prepare for and more effectively respond to rapidly spreading infections. Novavax is committed to using its technology platforms to create geographic-specific vaccine solutions and is therefore involved in several international partnerships, including collaborations with Cadila Pharmaceuticals of India, LG Life Sciences of Korea and PATH. Together, these organizations support Novavax' worldwide commercialization strategy and have the global reach to create real and lasting change in the biopharmaceutical field. Additional information about Novavax is available on the company's website, www.novavax.com .

CONTACT: Frederick W. Driscoll
         VP, Chief Financial Officer and Treasurer
         Novavax, Inc.
         240-268-2000